Radius Health (NASDAQ:RDUS) was upgraded by stock analysts at BidaskClub from a “strong sell” rating to a “sell” rating in a research note issued on Wednesday, December 27th.
Several other analysts also recently weighed in on RDUS. Maxim Group reaffirmed a “positive” rating on shares of Radius Health in a research note on Friday, September 29th. They noted that the move was a valuation call. Zacks Investment Research downgraded shares of Radius Health from a “hold” rating to a “sell” rating in a research note on Wednesday, October 4th. Goldman Sachs Group reissued a “neutral” rating and set a $45.00 price objective on shares of Radius Health in a report on Friday, October 6th. Jefferies Group cut their price objective on shares of Radius Health from $38.00 to $31.00 and set a “hold” rating on the stock in a report on Friday, November 3rd. Finally, Cantor Fitzgerald reissued a “buy” rating and set a $58.00 price objective on shares of Radius Health in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, six have issued a hold rating and five have issued a buy rating to the company’s stock. The company presently has an average rating of “Hold” and a consensus price target of $48.00.
Shares of Radius Health (NASDAQ:RDUS) opened at $35.37 on Wednesday. The company has a debt-to-equity ratio of 0.53, a current ratio of 12.87 and a quick ratio of 12.79. Radius Health has a 12 month low of $24.66 and a 12 month high of $49.16. The stock has a market cap of $1,580.00, a PE ratio of -6.51 and a beta of 1.10.
Radius Health (NASDAQ:RDUS) last posted its quarterly earnings results on Thursday, November 2nd. The biopharmaceutical company reported ($1.31) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.28) by ($0.03). The firm had revenue of $13.50 million for the quarter, compared to analysts’ expectations of $6.90 million. During the same period in the previous year, the company earned ($1.07) earnings per share. equities analysts forecast that Radius Health will post -5.57 EPS for the current year.
In related news, insider Jesper Hoiland acquired 6,800 shares of the company’s stock in a transaction dated Tuesday, November 7th. The shares were purchased at an average cost of $29.04 per share, with a total value of $197,472.00. Following the completion of the acquisition, the insider now directly owns 12,900 shares of the company’s stock, valued at $374,616. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, major shareholder Growth N. V. Biotech bought 50,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 14th. The shares were acquired at an average price of $26.25 per share, with a total value of $1,312,500.00. Following the completion of the transaction, the insider now directly owns 5,698,799 shares of the company’s stock, valued at $149,593,473.75. The disclosure for this purchase can be found here. Insiders acquired 158,578 shares of company stock worth $4,659,916 over the last ninety days. Corporate insiders own 15.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently bought and sold shares of RDUS. TimesSquare Capital Management LLC lifted its position in Radius Health by 184.6% during the third quarter. TimesSquare Capital Management LLC now owns 1,610,365 shares of the biopharmaceutical company’s stock valued at $62,080,000 after purchasing an additional 1,044,615 shares during the period. Farallon Capital Management LLC lifted its position in Radius Health by 18.3% during the second quarter. Farallon Capital Management LLC now owns 3,686,300 shares of the biopharmaceutical company’s stock valued at $166,731,000 after purchasing an additional 569,300 shares during the period. BB Biotech AG lifted its position in Radius Health by 11.0% during the second quarter. BB Biotech AG now owns 5,038,799 shares of the biopharmaceutical company’s stock valued at $227,905,000 after purchasing an additional 498,400 shares during the period. RA Capital Management LLC acquired a new position in Radius Health during the second quarter valued at $22,486,000. Finally, Point72 Asset Management L.P. acquired a new position in shares of Radius Health in the third quarter worth about $17,236,000.
TRADEMARK VIOLATION NOTICE: This news story was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another website, it was stolen and republished in violation of US and international trademark & copyright legislation. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/01/12/radius-health-rdus-upgraded-to-sell-by-bidaskclub.html.
About Radius Health
Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.
Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.